Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01138644 · ClinicalTrials.gov registry record
Atrial Fibrillation/Flutter Outcome Risk Determination
A clinical trial of Atrial Fibrillation and Atrial Flutter, sponsored by Vanderbilt University.
- Completed
- Registry status
- 519
- Enrollment target
- 1
- Study location
NCT01138644 is a study of Atrial Fibrillation and Atrial Flutter that has completed, run by Vanderbilt University. The registered enrollment target is 519 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01138644, a study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 519 participants
- Enrollment target
- 1
- Study location
Study Summary
It is our hypotheses that 1) readily available Emergency Department data can be utilized in an Atrial Fibrillation clinical prediction rule to identify those patients at low or high risk for adverse outcomes; 2) Assigned risk can be utilized to drive physician decision-making by identifying patients who do not require hospital admission (low risk) and patients needing hospitalization (high risk); and 3) a facile version of the AFPR will be easily incorporated into standard Emergency Department patient management systems and assist physicians with risk stratification of patients presenting with Atrial Fibrillation.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Emergency Medicine - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 519 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01138644
The ClinicalTrials.gov registry entry for NCT01138644 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 519 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (83% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT01138644 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01138644 about?
NCT01138644 is a clinical study titled "Atrial Fibrillation/Flutter Outcome Risk Determination". It is our hypotheses that 1) readily available Emergency Department data can be utilized in an Atrial Fibrillation clinical prediction rule to identify those patients at low or high risk for adverse outcomes; 2) Assigned risk can be utilized to drive physician decision-making by identifying patients...
What is the current status of trial NCT01138644?
This trial is currently completed. The enrollment target is 519 participants. The study started on 2010-06. Estimated completion is 2015-04.
What conditions does trial NCT01138644 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
Who is sponsoring clinical trial NCT01138644?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01138644 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.